[Is radical cystectomy indicated for the treatment of patients with bladder carcinoma N+ M0?]

Arch Esp Urol. 1991 Jan-Feb;44(1):39-44.
[Article in Spanish]

Abstract

The following parameters were analyzed in 55 patients with N + M0 bladder carcinoma: 1. Extent of lymph node involvement: A significant difference was observed for those with N1 whose 5 year survival rate is 46%, whereas those with N3, N4 did not survive at two years. 2.

Treatment: 29 patients underwent cystectomy and 26 did not. Of these 26 patients, 14 received polychemotherapy and 11 received only symptomatic treatment. Survivorship was significantly better for those who underwent cystectomy than those who received polychemotherapy, and it was better for this latter patient group than for those who received symptomatic treatment. 3. Finally, we studied the possible effect of changing the chemotherapeutic regimen on patient survival. Although patients treated with CMV or M-VAC have only a short follow-up, patient survival appears to be enhanced.

Publication types

  • Comparative Study
  • English Abstract

MeSH terms

  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carcinoma, Transitional Cell / mortality
  • Carcinoma, Transitional Cell / pathology
  • Carcinoma, Transitional Cell / surgery*
  • Carcinoma, Transitional Cell / therapy
  • Cisplatin / administration & dosage
  • Combined Modality Therapy
  • Cyclophosphamide / administration & dosage
  • Cystectomy* / methods
  • Doxorubicin / administration & dosage
  • Evaluation Studies as Topic
  • Female
  • Fluorouracil / administration & dosage
  • Humans
  • Lymph Node Excision*
  • Lymphatic Metastasis
  • Male
  • Methotrexate / administration & dosage
  • Middle Aged
  • Spain / epidemiology
  • Survival Rate
  • Urinary Bladder Neoplasms / mortality
  • Urinary Bladder Neoplasms / pathology
  • Urinary Bladder Neoplasms / surgery*
  • Urinary Bladder Neoplasms / therapy
  • Vinblastine / administration & dosage

Substances

  • Vinblastine
  • Doxorubicin
  • Cyclophosphamide
  • Cisplatin
  • Fluorouracil
  • Methotrexate

Supplementary concepts

  • CISCA protocol
  • M-VAC protocol